Kennedy Natalie N, Xia Yuhe, Barrett Tessa, Luttrell-Williams Elliot, Berland Todd, Cayne Neal, Garg Karan, Jacobowitz Glenn, Lamparello Patrick J, Maldonado Thomas S, Newman Jonathan, Sadek Mikel, Smilowitz Nathaniel R, Rockman Caron, Berger Jeffrey S
Leon H. Charney Division of Cardiology, Department of Medicine, NYU Grossman School of Medicine, New York, NY.
Division of Vascular and Endovascular Surgery, Department of Surgery, NYU Langone Health and Manhattan Veterans Affairs Hospital, New York, NY.
J Vasc Surg. 2025 Feb;81(2):432-440.e3. doi: 10.1016/j.jvs.2024.09.028. Epub 2024 Oct 1.
Patients with peripheral artery disease (PAD) undergo lower extremity revascularization (LER) for symptomatic relief or limb salvage. Despite LER, patients remain at increased risk of platelet-mediated complications, such as major adverse cardiac and limb events (MACLEs). Platelet activity is associated with cardiovascular events, yet little is known about the dynamic nature of platelet activity over time. We, therefore, investigated the change in platelet activity over time and its association with long-term cardiovascular risk.
Patients with PAD undergoing LER were enrolled into the multicenter, prospective Platelet Activity and Cardiovascular Events study. Platelet aggregation was assessed by light transmission aggregometry to submaximal epinephrine (0.4 μmol/L) immediately before LER, and on postoperative day 1 or 2 (POD1 or POD2) and 30 (POD30). A hyperreactive platelet phenotype was defined as >60% aggregation. Patients were followed longitudinally for MACLEs, defined as the composite of death, myocardial infarction, stroke, major lower extremity amputation, or acute limb ischemia leading to reintervention.
Among 287 patients undergoing LER, the mean age was 70 ± 11 years, 33% were female, 61% were White, and 89% were on baseline antiplatelet therapy. Platelet aggregation to submaximal epinephrine induced a bimodal response; 15.5%, 16.8%, and 16.4% of patients demonstrated a hyperreactive platelet phenotype at baseline, POD1, and POD30, respectively. Platelet aggregation increased by 18.5% (P = .001) from baseline to POD1, which subsequently returned to baseline at POD30. After a median follow-up of 19 months, MACLEs occurred in 165 patients (57%). After adjustment for demographics, clinical risk factors, procedure type, and antiplatelet therapy, platelet hyperreactivity at POD1 was associated with a significant hazard of long-term MACLE (adjusted hazard ratio, 4.61; 95% confidence interval, 2.08-10.20; P < .001).
Among patients with severe PAD, platelet activity increases after LER. Platelet hyperreactivity to submaximal epinephrine on POD1 is associated with long-term MACLE. Platelet activity after LER may represent a modifiable biomarker associated with excess cardiovascular risk.
外周动脉疾病(PAD)患者接受下肢血管重建术(LER)以缓解症状或挽救肢体。尽管进行了LER,但患者仍面临血小板介导的并发症风险增加,如主要不良心脏和肢体事件(MACLEs)。血小板活性与心血管事件相关,但关于血小板活性随时间的动态变化知之甚少。因此,我们研究了血小板活性随时间的变化及其与长期心血管风险的关联。
接受LER的PAD患者被纳入多中心前瞻性血小板活性与心血管事件研究。在LER前、术后第1天或第2天(POD1或POD2)以及第30天(POD30),通过光透射聚集法评估血小板对亚最大肾上腺素(0.4μmol/L)的聚集情况。高反应性血小板表型定义为聚集率>60%。对患者进行纵向随访,观察MACLEs,其定义为死亡、心肌梗死、中风、主要下肢截肢或导致再次干预的急性肢体缺血的复合事件。
在287例接受LER的患者中,平均年龄为70±11岁,33%为女性,61%为白人,89%接受基线抗血小板治疗。血小板对亚最大肾上腺素的聚集呈现双峰反应;分别有15.5%、16.8%和16.4%的患者在基线、POD1和POD30时表现出高反应性血小板表型。从基线到POD1,血小板聚集增加了18.5%(P = .001),随后在POD30时恢复到基线水平。中位随访19个月后,165例患者(57%)发生了MACLEs。在调整了人口统计学、临床危险因素、手术类型和抗血小板治疗后,POD1时的血小板高反应性与长期MACLE的显著风险相关(调整后的风险比为4.61;95%置信区间为2.08 - 10.20;P < .001)。
在重度PAD患者中,LER后血小板活性增加。POD1时血小板对亚最大肾上腺素的高反应性与长期MACLE相关。LER后的血小板活性可能代表一种与心血管风险过高相关的可改变生物标志物。